A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)

NCT00404833 Phase 3 COMPLETED

This is a prospective randomized open-label pilot study to investigate the effect of mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to membranous nephropathy (MN) or focal segmental glomerulosclerosis (FSGS). The change in urine protein excretion will be the primary outcome studied. The treatment regimen comprising prednisolone and mycophenolate mofetil will be compared with prednisolone and chlorambucil in MN, and compared with prednisolone in FSGS. The study duration will be 12 months for each patient.

Details

Lead sponsor	Hospital Authority, Hong Kong
Phase	Phase 3
Status	COMPLETED
Enrolment	16
Start date	2003-01
Completion	2006-12

Conditions

• Glomerulonephritis, Membranous
• Glomerulosclerosis, Focal

Interventions

• prednisolone and mycophenolate mofetil
• prednisolone and chlorambucil

Primary outcomes

• Proteinuria

Countries

China